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Testosterone Therapy in Adult Males
Abstract
Background:
Low testosterone (T) in men is a common medical condition affecting approximately 5 million men in the
United States. Low T caused by primary hypogonadism is treatable with exogenous testosterone in the form
of direct injection or topical gels. However, low T due to secondary hypogonadism is amenable to treatment
with exogenous testosterone forms, as well as selective estrogen receptor modulators (SERMs), such as
clomiphene citrate (Clomid; CC).There are significant side effects and increased cost with exogenous
testosterone therapy (mentioned above) compared to clomiphene. Generic clomiphene, used off-label, avoids
these side effects and represents a significant cost savings.But what is its efficacy compared to testosterone
therapy?
Methods:
An exhaustive search of available medical literature was conducted utilizing 3 separate, thoroughly vetted
search engines, including MEDLINE-Ovid, Web of Science, and CINAHL. Keywords used included:
clomiphene, hypogonadotropic hypogonadism, and ADAM or qADAM or quality of life.
Results:
Based on the search criteria, 6 articles were identified and reviewed for relevancy. This was narrowed down to
2 articles that met the inclusion and exclusion criteria. These 2 studies were observational, non-randomized
studies. One study found that there was no statistical difference between CC, injected testosterone, or
testosterone gel replacement therapy (TGRT) in regards to patient satisfaction as measured with the qADAM
questionnaire. The second study found that CC was as effective as TGRT at raising serum T levels at a much
lower cost without the same risks of side effects associated with TGRT.
The overall quality of both studies was low and further investigation would need to be done to validate these
findings. Specifically, randomized, placebo controlled, double blinded, studies with larger cohorts are
necessary.
Conclusion:
Clomiphene citrate has been used for many years in an off-label manner to treat men with hypogonadism,
mostly in specialty centers.There are only 2 studies found in the literature comparing CC to exogenous
testosterone treatment and both of are low quality. Despite this limitation, and a lack of FDA approval, CC
appears to be a viable option for men with low T due to secondary hypogonadism, demonstrating equal
improvement in overall patient satisfaction and quality of life improvements at a lower cost while avoiding the
potential side effects of testicular atrophy and reduced spermatogenesis.
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Abstract   
 
Background:  
Low testosterone (T) in men is a common medical condition affecting approximately 5 million 
men in the United States. Low T caused by primary hypogonadism is treatable with exogenous 
testosterone in the form of direct injection or topical gels. However, low T due to secondary 
hypogonadism is amenable to treatment with exogenous testosterone forms, as well as selective 
estrogen receptor modulators (SERMs), such as clomiphene citrate (Clomid; CC).There are 
significant side effects and increased cost with exogenous testosterone therapy (mentioned 
above) compared to clomiphene. Generic clomiphene, used off-label, avoids these side effects 
and represents a significant cost savings. But what is its efficacy compared to testosterone 
therapy? 
 
Methods:   
An exhaustive search of available medical literature was conducted utilizing 3 separate, 
thoroughly vetted search engines, including MEDLINE-Ovid, Web of Science, and CINAHL. 
Keywords used included: clomiphene, hypogonadotropic hypogonadism, and ADAM or 
qADAM or quality of life.  
 
Results:   
Based on the search criteria, 6 articles were identified and reviewed for relevancy. This was 
narrowed down to 2 articles that met the inclusion and exclusion criteria. These 2 studies were 
observational, non-randomized studies. One study found that there was no statistical difference 
between CC, injected testosterone, or testosterone gel replacement therapy (TGRT) in regards to 
patient satisfaction as measured with the qADAM questionnaire. The second study found that 
CC was as effective as TGRT at raising serum T levels at a much lower cost without the same 
risks of side effects associated with TGRT.  
The overall quality of both studies was low and further investigation would need to be done to 
validate these findings. Specifically, randomized, placebo controlled, double blinded, studies 
with larger cohorts are necessary.  
 
Conclusion:   
Clomiphene citrate has been used for many years in an off-label manner to treat men with 
hypogonadism, mostly in specialty centers. There are only 2 studies found in the literature 
comparing CC to exogenous testosterone treatment and both of are low quality. Despite this 
limitation, and a lack of FDA approval, CC appears to be a viable option for men with low T due 
to secondary hypogonadism, demonstrating equal improvement in overall patient satisfaction and 
quality of life improvements at a lower cost while avoiding the potential side effects of testicular 
atrophy and reduced spermatogenesis.  
 
Keywords:  Clomiphene citrate, hypogonadotropic hypogonadism, ADAM, qADAM, quality of 
life 
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The Effectiveness of Clomiphene Citrate Compared to Exogenous Testosterone 
Therapy in Adult Males 
BACKGROUND 
Low testosterone (T) in men is a common medical condition affecting approximately 5 
million men in the United States, though it is reported to be under diagnosed.1 It is estimated that 
fewer than 10% of men with low T in the US currently receive testosterone replacement 
therapy.2  Low T results in decreased muscle mass and strength, decreased libido, decreased 
sexual performance, symptoms of depression, increased fatigue, osteoporosis, and increased rates 
of cardiovascular disease, dyslipidemia, diabetes, metabolic syndrome, as well as all-cause 
mortality.3,4  Low serum testosterone in adult males may be due to primary testicular failure, in 
which the testes fail to produce endogenous testosterone, or secondary hypogonadism (AKA 
hypogonadotropic hypogonadism) which is much more common.5  In secondary hypogonadism, 
there is hypothalamic suppression of gonadotropin-releasing hormone, which in turn leads to 
decreased production of LH (luteinizing hormone) by the pituitary gland.5  LH is a necessary 
signal for the testes to produce testosterone.  
Low T caused by primary hypogonadism is treatable with exogenous testosterone in the 
form of direct injection or topical gels. However, low T due to secondary hypogonadism is 
amenable to treatment with exogenous testosterone forms, as well as selective estrogen receptor 
modulators (SERMs), such as clomiphene citrate (brand name: Clomid).6  Clomiphene citirate 
(CC) was first introduced in the 1960s and has become one of the most widely used medications 
to treat anovulation in women, for which it was originally approved by the United States Food 
and Drug Association (FDA). Despite not having FDA approval, it has been commonly used to 
treat male infertility due to hypogonadism.6  Clomiphene citrate, when prescribed off-label for 
hypogonadism, blocks the feedback inhibition of estradiol at the hypothalamus, which increases 
pituitary release of LH (luteinizing hormone) and FSH (follicle stimulating hormone).6  LH and 
FSH in turn stimulate the Leydig and Sertoli cells of the testes to produce serum testosterone and 
spermatogenesis, respectively.6  See figure I for a representation of the pituitary feedback control 
of LH, FSH and testosterone from estrogen (E2). This increase in serum testosterone has led 
many providers to use CC off-label, not only for male infertility, but also for the symptoms of 
low testosterone.  
Testosterone injections or topical gels have been the mainstay of treatment for low T. 
Exogenous testosterone effects the hypothalamic-pituitary-gonadal axis (HPG axis) resulting in 
reduced spermatogenesis, and eventually can lead to testicular atrophy.7  Reduced 
spermatogenesis is particularly problematic for men wishing to preserve fertility. There are 
significant side effects and increased cost with exogenous testosterone therapy (mentioned 
above) compared to clomiphene. Generic clomiphene, used off-label, avoids these side effects 
and represents a significant cost savings.6  Can clomiphene citrate provide effective symptomatic 
relief compared to exogenous testosterone therapy?   
METHODS 
An exhaustive search of available medical literature was conducted utilizing three 
separate, search engines, including MEDLINE-Ovid, Web of Science, and CINAHL. Relevant 
articles were assessed for quality using the GRADE system. Keywords used to search included: 
clomiphene, hypogonadotropic hypogonadism, and ADAM or qADAM or quality of life. 
Eligibility criteria included studies comparing clomiphene citrate vs. exogenous testosterone 
therapy (IM injection or topical gels) and included study outcomes that measure both serum 
testosterone levels and subjective symptom measures with the ADAM or qADAM questionnaire. 
Further more, studies had to be published in the English language. Exclusion criteria included 
non-comparative studies, those conducted prior to the year 2000, case studies and systematic 
reviews. Relevant articles were assessed for quality using the GRADE system.8 
RESULTS 
 The search strategy resulted in a six total articles; however, only two met eligibility 
criteria. Both articles 6,7 were observational studies and retrospective in nature. See Table I. 
Ramasamy et al 
 
This study7 was a retrospective cross-sectional design in which adult males were treated 
with either clomiphene citrate, testosterone injections, or testosterone gels for symptomatic 
hypogonadism (total T less than 300ng/dl). Patients reported satisfaction with their treatment 
regimen using the qADAM questionnaire. The qADAM questionnaire consists of 10 questions 
related to the symptoms of hypogonadism. Patients score each question with a possible range of 
1 to 5, with 1 representing maximal symptoms and 5 represents complete absence of symptoms. 
Total qADAM score can range from 10 to 50, with a lower score indicating more severe 
hypogonadal symptoms.9  Pre and post treatment serum testosterone and estradiol levels were 
measured for efficacy. There were 93 patients who were age matched from a retrospective cohort 
of 1150 men on testosterone replacement therapy (TST): 31 on testosterone injections, 31 on 
topical testosterone gels and, 31 on clomiphene citrate. This was compared to 31 men who 
received no testosterone therapy at all and had a serum T > 300ng/dl. There was no difference in 
median age between men taking CC (40.9), T injections (40.5), T gels (43.9) and controls (40.5).  
Median serum testosterone increases were reported as follows: CC was 247 to 504ng/dl, injected 
T was 224 to 1104ng/dl, topical T gels was 230 to 412ng/dl (p<0.05). Not surprisingly, men 
from the control group that did not receive TST, had significantly lower serum T levels than 
those that did receive TST. Despite a large difference in pre and post treatment serum T levels 
between injectable T and CC or T gels, there was not a statistical difference in overall qADAM 
scores measured at post-treatment: 35 for CC, 39 for injectable T and 36 for T gels (p>0.05). One 
notable exception from the qADAM questionnaire was that men receiving T injections reported 
greater libido than men receiving CC (4 vs 3, p <0.04) or T gels (4 vs 3, p = 0.04), or controls (4 
vs 3, p <0.01). See Table II. 
With the exception of libido, which was significantly higher with the injected T group (p 
= 0.04), no statistical difference was seen in the qADAM scores of patients treated with CC, 
injected T, or T gels. This is despite the much higher serum T levels achieved with injected T. As 
a result, there does not appear to be an overall correlation with supraphysiologic T levels 
achieved with injected T and symptom relief. Therefore, this study suggests that CC could be as 
effective as injected and/or topical gel T, while having fewer potential side effects.  
The authors discuss some limitations surrounding their study. Primarily, they state the 
study was limited by its retrospective, cross-sectional design and the fact that pretreatment 
qADAM values were not available. Serum T levels were drawn at the same time that qADAM 
questionnaires were collected from patients. However, there was no control over the timing of 
the patient’s T injections. Patient’s receiving T injections experience a peak and trough effect of 
serum T, with much higher levels recorded in the first few days post-injection. The authors 
suggest that the statistically higher serum T levels seen with men in the injected T group could 
have been due to these men receiving their T injections in the 3 to 4 days prior to their blood 
draw. They also discuss a lack of specificity in regards to the qADAM questionnaire. This is due 
to positive responses being possibly correlated to other conditions, such as depression.  
 
Taylor et al 
 
In this retrospective cohort study6 104 male patients with low serum T (defined as serum 
T < 300ng/dl) or with male infertility were given testosterone gel replacement therapy (39 
TGRT) or clomiphene citrate (65 CC) at the discretion of the treating physician. Of the TGRT 
group, 100% of the patients were being treated for complaints related to hypogonadism. For the 
CC group, 65% of patients were being treated for complaints related to hypogonadism, whereas 
35% were being treated for MI with related symptoms of hypogonadism. For purposes of this 
study, biochemical efficacy was defined as an elevation of serum T to the mid-normal range. The 
authors define mid-normal range as a serum T of approximately 550ng/dl. Patients in the CC 
group were all started at 50mg every other day. They were then titrated up to 100mg every other 
day, or titrated down to 25mg every other day in order to achieve a mid-normal range serum T. 
Men taking TGRT were started at dose of 5mg of either 1% Androgel® or 1% Testim® with a 
similar titration strategy to biochemical efficacy, though the frequency or range of dosing was 
not disclosed. Males with high pretreatment luteinizing hormone (LH) levels, indicating likely 
primary testicular failure, were not offered CC, but may have received TGRT instead. This 
decision was based on the fact that CC works by up-regulating the hypothalamic-pituitary-
gonadal axis to increase T production by normally functioning testis in males with secondary 
hypogonadism. Pre and post treatment ADAM scores were collected on the CC patients only and 
were obtained via office or telephone interviewing. Patients reported satisfaction with their 
treatment regimen using the ADAM questionnaire. The ADAM questionnaire consists of 10 
questions related to the symptoms of hypogonadism. Each question is assigned 1 point of value 
for a yes answer, zero points for a no answer. A higher score indicates more severe symptoms 
compared to a lower score. 10  This should not be confused with the newer qADAM 
questionnaire, which gives a higher score to patients who have low to absent hypogonadal 
symptoms. Average age at treatment initiation was 42 for the CC group and 57 for the TGRT 
group. Average follow up was 23 months for CC and 46 month for TGRT. Average post 
treatment serum T was 573ng/dl for CC and 553ng/dl for TGRT (p < 0.001). This reflected an 
average serum T increase of 296ng/dl in the CC group and 332ng/dl in the TGRT group. Both 
treatments had statistically significant increases in post treatment serum T. Among CC patients, 
the average pre treatment ADAM score was 4.9 and post treatment was 2.1. (P<0.05). ADAM 
questions specifically related to sexual function domain was 0.76 vs. 0.23 at follow up (p<0.05). 
Ninety-one percent of the patients responded to the ADAM questionnaire with an improved 
score compared to pretreatment levels. No adverse events were reported in either group. Monthly 
cost of TGRT ranged from $265 to $270, versus CC (50mg every other day) reported at $83.  
The authors conclude that compared to TGRT, clomiphene citrate demonstrated 
biochemical and clinical efficacy at a lower cost. The authors of this study do not discuss 
limitations of their study. 
DISCUSSION 
The mainstay of FDA approved therapy for men with low T caused by both primary and 
secondary hypogonadism has been in the form of exogenous testosterone replacement, given as 
an intramuscular injection or topical gel. While exogenous T has been proven to be effective at 
raising serum T levels and improving symptoms, it does not mimic normal circadian hormone 
release.6  Exogenous T therapy is known to have significant side effects, namely the possibility 
of testicular atrophy and infertility due to negative feedback of the hypothalamic-pituitary-
gonadal (HPG) axis. Clomiphene citrate, on the other hand, influences the HPG axis by blocking 
feedback estradiol receptors at the hypothalamus, which results in the increased production of 
endogenous testosterone by the testes through an increase in LH secretion by the anterior 
pituitary gland. This increase in the body’s own endogenous testosterone secondary to 
administering CC has seemed to reflect restorative effects on the HPG axis.2  
While there are only 2 studies found in the literature directly comparing CC to exogenous 
T therapies, the literature clearly supports the biochemical efficacy of CC treatment in 
hypogonadism.6  As a result of CC’s mechanism of action, it avoids the common side effects 
experienced with exogenous T therapy.  This may be especially important for younger male 
patients who wish to preserve their fertility. 
Currently, CC is only approved by the FDA for the treatment of ovulatory dysfunction in 
females wishing to become pregnant. Recently, Repros Therapeutics, Inc. has submitted an FDA 
new drug application for Androxal for the treatment of secondary hypogonadism. Androxal is the 
single isomer of CC. Currently a decision on approval by the FDA is pending.11 
Testosterone injections have to be administered weekly and require patients to be seen in 
clinic for their injections. This increases costs in addition to the cost of the drug itself. There is 
also a peak and trough effect of serum T levels experienced by patients receiving intramuscular 
(IM) testosterone injections. TGRT therapy overcomes this inconsistent serum T level versus IM 
injections, but carries with it the risk of skin irritation and cross contamination to household 
members, including children.6  
Additionally the following costs were recently found via GoodRx.com12: TGRT, even 
in the generic form, ranges from $176 to $344 per month. CC on the other hand, can be 
purchased for $31 to $45 per month in the 50mg form which can be cut in half, since most 
patients are prescribed 25mg of CC daily.1  This brings the monthly cost down to the range of 
$15.50 to $22.50 per month. It should be noted that drug prices are constantly changing due to 
geographic differences as well as generic status changes. But the possible decrease in cost to the 
patient is still significant. 
Ideally, further studies should be conducted in regards to CC for patients with 
hypogonadism. Both studies6,7 reviewed in this analysis were determined to be of very low-
quality utilizing the GRADE system. Both studies6,7 where retrospective cohort studies and had 
small sample sizes. Only one study (Ramasamy et al7) performed age matching. Ramasamy et al7 
disclosed significant funding via pharmaceutical company Repros, which may introduce possible 
bias related to industry objectives. Frequent off-label use of CC, along with the possible entry of 
a single isomer of CC to the market (Androxal), will likely shed more light on the use of SERMs 
for hypogonadism and potentially encourage more studies of higher quality to be conducted.  
CONCLUSION 
Clomiphene citrate has been used for many years in an off-label manner to treat men with 
hypogonadism, mostly in specialty centers.  Of the only 2 studies found in the literature 
comparing CC to exogenous testosterone treatment, both of are very low quality. Despite this 
limitation, and a lack of FDA approval, CC appears to be a viable option for men with low T due 
to secondary hypogonadism, demonstrating equal improvement in overall patient satisfaction and 
quality of life improvements while avoiding the potential side effects of testicular atrophy and 
reduced spermatogenesis. Furthermore, a significant cost savings exists for patients treated with 
CC, though the cost savings is constantly changing. Despite the overall quality of the 
comparative data found in the literature, enough evidence exists to warrant further research on 
this drug in order to treat patients with less risks at a lower cost.   
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Table I. Characteristics of Reviewed Studies  
GRADE Quality Assessment  
GRADE Quality Assessment  
 
Downgrade Criteria 
Quality 
Study Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
     
Ramasamy et al7 Retrospective cross-sectional design a Serious b None Serious c Not serious  Yes d Very Low 
Taylor et al6 Retrospective cohort Serious e None Serious c Not serious No Very Low 
a Age matched from retrospective cohort of 1,150 
b Duration of treatment not mentioned. Timing of serum T measurements was not controlled. Single center. Pretreatment subjective   
questionnaires were not collected. 
c Confidence intervals not mentioned; Small sample size. 
d Financial interests and/or other relationship with Auxilium, Endo and Repros. 
e Patients were not age matched. ADAM scores only collected on CC group. Decision to treat with CC or TGRT left to treating physician 
discretion.  Single center. 
Tables II - III. Summary of Findings 
Table II. Ramasamy et al7 
Median +/- IQR 
Intervention Injected T (n=31) Gel (n=31) CC (n=31) Control (n=31) P value 
Age 40.5 +/- 9.2 43.9 +/- 13.7 40.9 +/- 9.4 40.5 +/- 10.4 p >0.05 
Pre treatment serum T (ng/dl) 223.5 +/- 182.5 230.0 +/- 151.0 247.0 +/- 66.5 310.0 +/- 136.0  
Post treatment serum T (ng/dl) 1,104.0 +/- 866.5 412.0 +/- 339.0 503.5 +/- 306.8 __ p <0.05 
Change in serum T (ng/dl) 956 +/- 879.0 243.0 +/- 375.5 271.5 +/- 325.8 __ p <0.05 
qADAM (range 10-50) 39 +/- 8 36 +/- 9  35 +/- 8 34 +/- 9  p >0.05 
Libido question from qADAM (range 1-5) 4.0 +/- 1.0 3.0 +/- 1.0 3.0 +/- 1.0 3.0 +/- 1.5 p <0.05 
Table III. Taylor et al6 
Intervention Gel (n=39) CC (n=65) P value 
Age 57 (30 – 78) 42 (19 – 70) p <0.05 
Average follow up 46 months (range 6 – 149) 23 months (range 8-40) __ 
Average Pre treatment serum T (ng/dl) 221 (27 – 363) 277 (16 – 381) p <0.05 
Average Post treatment serum T (ng/dl) 553 573 p <0.05 
Average Change in serum T (ng/dl) 332 296 p <0.05 
Average pre treatment ADAM score  __ 4.9 p <0.05 
Average post treatment ADAM score  __ 2.1 p <0.05 
Pre treatment sexual function questions from 
qADAM  __ 0.76 p <0.05 
Post treatment sexual function questions from 
qADAM __ 0.23 p <0.05 
 
  
Figure I. Pituitary feedback control of LH, FSH and 
Testosterone from Estrogen (E2). Diagram is courtesy of Dr Rochira.14  
 
[Figure redacted for online publication due to copyright.  
See Figure 5 here: http://www.eje-online.org/content/155/4/513.figures-only]  
 
  
Appendix A. – qADAM Questionnaire15   
 
 
 
 
 
Appendix B. – St. Louis University ADAM Questionnaire15  
 
 
 
 
 
 
 
 
